Important Milestone Reached for Evaxion Biotech's EVX-01 Personalized Cancer TherapyGlobeNewsWire • 09/21/22
Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical SchoolGlobeNewsWire • 09/06/22
Evaxion Biotech A/S (EVAX) CEO Lars Wegner on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/22
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10GlobeNewsWire • 07/29/22
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung CancerGlobeNewsWire • 06/23/22
Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' NowZacks Investment Research • 06/08/22
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park CapitalGlobeNewsWire • 06/07/22
Evaxion Biotech A/S' (EVAX) CEO Lars Wegner on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/22
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02GlobeNewsWire • 05/10/22
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11GlobeNewsWire • 04/29/22
Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage MelanomaBusiness Wire • 04/26/22
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/22/22